Sutro Biopharma Inc (NAS:STRO)
$ 2.65 -0.04 (-1.49%) Market Cap: 218.52 Mil Enterprise Value: -144.87 Mil PE Ratio: 0 PB Ratio: 1.96 GF Score: 64/100

Sutro Biopharma Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 07:15PM GMT
Release Date Price: $7.67 (+4.92%)
Matthew Alexander Bannon
JPMorgan Chase & Co, Research Division - Former Analyst

Hello, everyone. Welcome to JPMorgan Healthcare Conference. My name is Matt Bannon. I'm a health care banker here at JPM. I am really excited to be setting the stage for a next presenting company, Sutro Biopharma. And presenting on behalf of Sutro, we have CEO, Bill Newell.

William J. Newell
Sutro Biopharma, Inc. - CEO & Director

Thank you, Matt, and thank you to JPMorgan for giving us the opportunity to help you all close out the conference this year. I'm Bill Newell, I'm the CEO of Sutro Biopharma. And as you might imagine, in my discussions today with you, we're going to make some forward-looking statements and our legal team appreciates it, if you would pay attention to this slide because it indicates things that you need to know about those forward-looking statements.

When I first came to Sutro in 2009, I was the 19th employee. We had a novel proprietary cell-free protein synthesis platform, it was unique and it was a long way away from being where we are

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot